Clinically used PARP inhibitors (PARPi) take advantage of the vulnerability of cancer cells (e.g., ovarian and breast carcinomas) that carry mutations in the DNA repair genes BRCA1/2, rendering them sensitive to DNA repair inhibitors, such as PARPi compounds. This evidence concerns the gene PARP1 and cancer.